Hannah Valantine - Jan 16, 2024 Form 4 Insider Report for BridgeBio Pharma, Inc. (BBIO)

Role
Director
Signature
Brian C. Stephenson, Attorney-in-Fact
Stock symbol
BBIO
Transactions as of
Jan 16, 2024
Transactions value $
-$86,051
Form type
4
Date filed
1/18/2024, 04:10 PM
Previous filing
Feb 13, 2024
Next filing
Feb 20, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BBIO Common Stock Options Exercise $24.6K +2.92K +165.25% $8.45* 4.68K Jan 16, 2024 Direct F1
transaction BBIO Common Stock Sale -$111K -2.92K -62.3% $37.97 1.76K Jan 16, 2024 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BBIO Stock Option (right to buy) Options Exercise $0 -2.92K -2.94% $0.00 96.2K Jan 16, 2024 Common Stock 2.92K $8.45 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on August 16, 2023.
F2 1/3rd of the shares underlying the option vested on June 22, 2023; thereafter, 1/3rd of the underlying shares vest on an annual basis, so that all of the underlying shares will be vested on June 22, 2025, subject to the optionee's continued service on the Board of Directors of the Company.